Spinal cord injury (SCI) results in paralysis, driven partly by widespread glutamate-induced secondary excitotoxic neuronal cell death in and around the injury site. While there is no curative treatment, the standard of care often requires interventive decompression surgery and repair of the damaged dura mater close to the injury locus using dural substitutes. Such intervention provides an opportunity for early and local delivery of therapeutics directly to the injured cord via a drug-loaded synthetic dural substitute for localized pharmacological therapy. Riluzole, a glutamate-release inhibitor, has shown neuroprotective potential in patients with traumatic SCI, and therefore, this study aimed to develop an electrospun riluzole-loaded synthetic dural substitute patch suitable for the treatment of glutamate-induced injury in neurons. A glutamate-induced excitotoxicity was optimized in SH-SY5Y cells by exploring the effect of glutamate concentration and exposure duration. The most effective timing for administering riluzole was found to be at the onset of glutamate release as this helped to limit extended periods of glutamate-induced excitotoxic cell death. Riluzole-loaded patches were prepared by using blend electrospinning. Physicochemical characterization of the patches showed the successful encapsulation of riluzole within polycaprolactone fibers. A drug release study showed an initial burst release of riluzole within the first 24 h, followed by a sustained release of the drug over 52 days to up to approximately 400 μg released for the highest loading of riluzole within fiber patches. Finally, riluzole eluted from electrospun fibers remained pharmacologically active and was capable of counteracting glutamate-induced excitotoxicity in SH-SY5Y cells, suggesting the clinical potential of riluzole-loaded dural substitutes in counteracting the effects of secondary injury in the injured spinal cord.

• Klíčová slova
• SH-SY5Y, electrospinning, glutamate-induced excitotoxicity, riluzole, spinal cord injury,
• MeSH
• implantované léky MeSH
• kyselina glutamová metabolismus   MeSH
• lidé MeSH
• nádorové buněčné linie MeSH
• neurony účinky léků   MeSH
• neuroprotektivní látky * aplikace a dávkování   chemie   farmakologie   MeSH
• polyestery chemie   MeSH
• poranění míchy * farmakoterapie   MeSH
• riluzol * aplikace a dávkování   chemie   farmakologie   MeSH
• uvolňování léčiv MeSH
• zvířata MeSH
• Check Tag
• lidé MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• implantované léky MeSH
• kyselina glutamová MeSH
• neuroprotektivní látky * MeSH
• polyestery MeSH
• riluzol * MeSH

Xe-Derma(®) is a new biological acellular temporary wound cover derived from pig dermis in the form of a mesh of collagen and elastic fibers. It is recommended for use in similar indications as classical pig xenografts. A data collection of 2 burns centres in the treatment of burns with Xe-Derma(®) was obtained from the medical records of 101 patients admitted from January 1, 2010 to December 31, 2011. The primary objectives of the study were to assess efficacy and safety when using Xe-Derma(®) in burn treatment, and to analyse the course of healing. The secondary objectives were to define the suitable spectrum of indications of Xe-Derma(®) in terms of burn depth, and to evaluate subsequent scarring using the Vancouver Scar Scale. No undesirable systemic effects or adverse device events were observed. The use of Xe-Derma(®) was not associated with a higher risk of burn wound infection. On the other hand, the infection was the most common cause of Xe-Derma(®) dissolution. The majority of patients (81.4%) had no signs of Xe-Derma(®) dissolution. The mean healing time in the group of patiens under review was close to 12 days and mean hospitalization time was almost 14 days. Using Xe-Derma(®) proved to be effective as a temporary covering for partial-thickness burns with the capacity of spontaneous healing. It proved to be a well-tolerated wound coverage with minimal complications and low level of pain during dressing changes. Xe-Derma(®) firmly adhered to the wound bed. There was a lower frequency of wound dressing changes and only a minimal rate of wound infection.

Le Xe-Derma® est un nouveau pansement acellulaire biologique provisoire à base de derme porcin, se présentant sous la forme d’un filet de fibres de collagène et d’élastine. Son utilisation est recommandée dans les indications similaires aux xenogreffes porcines classiques. Nous avons recueilli et analysé les données de 101 patients, dont les brûlures ont été traitées par Xe- Derma® dans 2 centres de grands brûlés entre le 1er janvier 2010 et le 31 décembre 2011. L’objectif principal de cette étude consistait à évaluer l’efficacité et la sécurité de l’utilisation du Xe-Derma® pour le traitement des brûlures et d’analyser le processus de guérison. Les objectifs secondaires étaient de déterminer un spectre d’indications pour l’utilisation du Xe-Derma® selon la gravité de la brûlure et d’évaluer le processus de cicatrisation consécutif à l’aide de la VSS (Vancouver Scar Scale, échelle cicatricielle de Vancouver). Aucun effet systémique défavorable ou effet local indésirable n’a été observé. L’utilisation du Xe-Derma® n’a pas été associée à un risque plus élevé d’apparition d’infections de la plaie. En revanche, les infections ont représenté la cause la plus fréquente de dissolution du Xe-Derma®. La majorité des patients (81,4%) n’ont toutefois manifesté aucun signe de dissolution du Xe-Derma®. Quelle que soit la gravité de la brûlure, le durée moyenne de guérison était proche de 12 jours et la durée moyenne d’hospitalisation était de presque 14 jours. L’utilisation du Xe-Derma® s’est avérée efficace en tant que pansement provisoire sur les brûlures de second degré, présentant un potentiel de guérison spontanée. Le Xe-Derma® est un pansement bien toléré, causant peu de complications et réduisant la douleur lors des changements de pansement. Il adhère très bien au fond de la plaie. La faible fréquence de changement de pansement a permis de limiter les infections des brûlures.

• Klíčová slova
• Xe-Derma®, acellular pig skin, biological temporary wound cover, burns,
• Publikační typ
• časopisecké články MeSH